Edwards Lifesciences (EW) Tops Q4 EPS by 1c; Guides Above the Street
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Edwards Lifesciences Reports Fourth Quarter Results
February 2, 2016 4:15 PM ESTIRVINE, Calif., Feb. 2, 2016 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today reported financial results for the quarter ended December 31, 2015.
Â
Fourth Quarter and Recent Highlights:
Global sales grew 8.6% to $671.1 million, and underlying1 sales were up 15.1%. Global THV sales grew 25.0%, and underlying sales were up 32.4%. Results reflect 2-for-1 stock split completed in December 2015. GAAP EPS was $0.64, an increase of 28.0%, and non-GAAP EPS grew... More